Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. (Q46656670)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

title

Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

Jerzy Roman Kowalczyk

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Michał Matysiak

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Jacek Wachowiak

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

9

Radwanska U

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

2

Balwierz W

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Danuta Sońta-Jakimczyk

11

object named as

Sonta-Jakimczyk D

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

3

Armata J

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

13

Wysocki M

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

5

Chybicka A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Roma Rokicka-Milewska

10

object named as

Rokicka-Milewska R

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Dluzniewska A

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Balcerska A

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Ochocka M

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 December 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

2117-2124

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107894%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403892

5 January 2020

exact match

0 references

cites work

Toxicity and effectiveness of high-dose idarubicin during AML induction therapy: results of a pilot study in children.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403892

Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403892

Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403892

A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Onco

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403892

Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403892

FLT3-TKD mutation in childhood acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403892

PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403892

Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403892

7 January 2021

Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403892

7 January 2021

Treatment outcome and prognostic factors in childhood acute myeloblastic leukemia: a report from the Japanese Children's Cancer and Leukemia Study Group (CCLSG)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403892

7 January 2021

Immunological classification of acute myeloblastic leukemias: relevance to patient outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403892

7 January 2021